**Title:** Effect of Teriflunomide in Subgroups Defined by Prior Treatment: Pooled Analysis of the Phase 2 study and the Phase 3 TEMSO, TOWER, and TENERE Studies

Short title for Annual Meeting Mobile Application:

Effect of teriflunomide by prior treatment

**Authors:**

Comi G,1 Freedman MS,2 Meca-Lallana J,3 Vermersch P,4 Kim B,5 Parajeles K,6 Edwards K,7 Gold R,8 Overell J,9 Korideck H,10 Chavin J,10 Poole E,10 Coyle P11

1University Vita-Salute San Raffaele, Milan, Italy
2University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
3Hospital Virgen de la Arrixaca, Unidad de Esclerosis Múltiple, Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM Universidad Católica San Antonio de Murcia, Murcia, Spain
4University of Lille, Lille, France
5Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
6Hospital San Juan de Dios, San José, Costa Rica
7Multiple Sclerosis Center of Northeastern New York, NY, USA
8St Josef Hospital, Ruhr University Bochum, Bochum, Germany
9Institute of Neurological Sciences, Glasgow University, Glasgow, United Kingdom
10Sanofi, Cambridge, MA, USA
11Stony Brook MS Comprehensive Care Center, School of Medicine, Stony Brook University, Stony Brook, NY, USA
**Background**
Teriflunomide is a once-daily oral immunomodulator approved for treatment of relapsing forms of MS. The efficacy and safety of teriflunomide have been established in a Phase 2 (NCT01487096) study and the Phase 3 TEMSO (NCT00134563), TOWER (NCT00751881), and TENERE (NCT00883337) studies.

**Objective**
To investigate the efficacy/safety of teriflunomide in subgroups defined by prior treatment in a pooled post hoc analysis of the Phase 2 study and the Phase 3 TEMSO, TOWER, and TENERE studies.

**Methods**
In the Phase 2, TEMSO and TOWER studies, patients were randomized 1:1:1 to receive placebo, teriflunomide 7 mg, or teriflunomide 14 mg. In TENERE, patients were randomized 1:1:1 to receive subcutaneous interferon beta-1a, teriflunomide 7 mg, or teriflunomide 14 mg. Post hoc analysis of annualized relapse rate (ARR) was carried out for patients according to subgroups defined by prior MS treatment: Group 1, patients whose last DMT was discontinued within 6 months before randomization; Group 2, patients whose last DMT was discontinued 6 months to 2 years before randomization; and Group 3, patients who received no prior DMT. Data are reported for teriflunomide 14 mg and placebo groups.

**Results**
The pooled population included 2643 patients; 348, 412, and 1883 were in Groups 1, 2, and 3, respectively. ARR was statistically significantly lower in patients treated with teriflunomide 14 mg compared with placebo, regardless of prior treatment status: Group 1, 0.45 vs 0.81 (45% relative reduction; P=0.0029); Group 2, 0.53 vs 0.79 (34% relative reduction; P=0.0117), Group 3, 0.33 vs 0.53 (38% relative reduction; P<0.0001).
Conclusions
In this pooled analysis, the treatment effect of teriflunomide was consistent across subgroups of patients defined by prior MS treatment. Although patients with prior DMT use had a higher level of baseline disease activity than patients with no prior DMT use, teriflunomide demonstrated similar efficacy in subgroups.

Disclosures:
GC: Compensation for consulting services and/or speaking activities from Almirall, Biogen, Celgene, Excemed, Forward Pharma, Genzyme, Merck, Novartis, Receptos, Roche, Sanofi, and Teva; fees for non-CME services from Almirall, Bayer, Biogen, Excemed, Genzyme, Merck Serono, Novartis, Receptos, Sanofi, SSIF, and Teva
MF: Research/educational grant support from Bayer and Genzyme; honoraria/consulting fees from Bayer, Biogen, EMD Canada, Novartis, Sanofi, and Teva; member of company advisory boards/board of directors/other similar group for Bayer, Biogen, Chugai, Merck Serono, Novartis, Opexa Therapeutics, Sanofi, and Teva
JML: Consulting fees from Almirall, Biogen, Merck Serono, Novartis, Sanofi, and Teva
PV: Honoraria, consulting fees from Almirall, Bayer, Biogen, Celgene, Genzyme, Sanofi, GSK, Merck Serono, Novartis, Servier, and Teva; research support from Bayer, Biogen, Genzyme, Sanofi, and Merck Serono
BK: Nothing to disclose
KE: Consulting fees from Biogen, Genzyme, EMD Serono; research support from Biogen, Eli Lilly, Genentech, Sanofi, and Hoffmann-La Roche, Novartis
RG: Consulting fees from Bayer, Biogen, Elan, Genzyme, Roche, and Teva; grant/research support from Bayer, Biogen, Genzyme, and Teva
JO: Speakers fees, advisory fees, travel, and hospitality from Roche, Biogen, Novartis, Teva, Merck, Medday, Allergan, Celgene, and Genzyme; Research and departmental funds from Novartis, Biogen, Roche, Genzyme, and Merck
HK: Employee of Sanofi with ownership interest
JC: Employee of Sanofi with ownership interest
EP: Employee of Sanofi with ownership interest
**PC:** Consulting fees from Accordant, Acorda, Bayer, Biogen, Celgene, Genentech, Roche, Genzyme, Sanofi, Novartis, Serono, and Teva; research support from Actelion, Alkermes, Genentech, Roche, MedDay, NINDS, and Novartis

Study supported by Sanofi

**Submission information**

**Type:** Oral or poster presentation

**Presenting author:** Giancarlo Comi, University Vita-Salute San Raffaele, Olgettina Street, 58, Milan 20132, Milan, Italy; Phone: +39-02-26432990; email: comi.giancarlo@hsr.it